Europe finds itself in a peculiar bind. Its laboratories and universities consistently produce groundbreaking research, yet the continent rarely transforms that scientific edge into globally dominant companies. The problem, as former Italian Prime Minister Enrico Letta outlines, is not a lack of ideas but a failure of the ecosystem that should nurture them from the lab bench to the marketplace.
Nowhere is this disconnect more acute than in health and life sciences. The European Commission's own 2025 Biotech Act paints a stark picture: between 2015 and June 2025, biopharma start-ups in the United States attracted roughly €219 billion in health biotechnology venture capital. Their European counterparts managed just €25 billion — a ninefold gap in late-stage funding. The numbers tell a story of capital flowing to markets where scale is immediate and rewards are swift.
The Clinical Trial Exodus
The disparity extends beyond finance. The European Economic Area's share of global clinical trials halved from 18% in 2013 to 9% in 2023. Meanwhile, China's share surged from under 10% to nearly 30%. New treatments reach American patients first, and even after European approval, fragmented national health systems deliver them unevenly. A patient in Stockholm may access a therapy months before one in Bucharest, if at all.
Letta, who prepared a report on the future of the Single Market, heard a recurring lament from young entrepreneurs: "We love Europe, but if we want to grow, we have to leave." That sentiment, he argues, is a slow bleed of the continent's future. A Europe that cannot retain its own dreamers is a Europe ceding its place in the innovation race.
The race that will define this century is not won by the first inventor but by the one who can finance, test, manufacture, and scale fastest. The United States combines deep capital pools with a vast internal market that rewards bold ideas almost overnight. China pours extraordinary public resources not just into science but into its commercialization. Europe, by contrast, remains a collection of twenty-seven distinct markets, each with its own regulatory hurdles, pricing regimes, and reimbursement timelines.
The Fifth Freedom
Letta's proposed remedy is a "Fifth Freedom" — the free movement of knowledge, research, and innovation — to sit alongside the existing four freedoms of goods, services, capital, and people. The idea is to create a seamless continental space where a start-up in Lisbon can find investors in Paris, scientists in Warsaw, and a factory site in Milan without ever needing to cross an ocean.
Health illustrates both the problem and the promise. Europe's public health systems hold some of the richest medical data on earth. Used responsibly and shared across borders, that knowledge could make the continent a world leader in precision medicine and next-generation therapies. But without the courage to connect it, fund it, and let it grow on a continental scale, Europe risks becoming a mere market for foreign industries.
The test, Letta says, is simple: the next generation of European biotech founders should be able to build their company, raise their funding, and reach their patients without ever leaving the continent. That requires not just policy documents but a genuine commitment to breaking down the barriers that keep brilliant science trapped in a fragmented economy.
As leaders on both sides of the Atlantic talk of reshoring and industrial sovereignty, Europe must first answer an honest question: bring back to what? Without a large, open, and worth-betting-on health market, no amount of strategy will keep companies here. The Fifth Freedom is not a slogan — it is a necessary evolution of the Single Market, and the clock is ticking.
